HAT Platform, Drugs for Neglected Diseases <em>initiative</em>, Avenue Milambo, N 4, Quartier Socimat, Gombe, Kinshasa 7948, Democratic Republic of the Congo
Dr. Florent Mbo
HAT Platform, Drugs for Neglected Diseases <em>initiative</em>, Avenue Milambo, N 4, Quartier Socimat, Gombe, Kinshasa 7948, Democratic Republic of the Congo
Background: The number of human African trypanosomiasis (HAT) cases in the Democratic Republic of Congo (DRC) has significantly reduced, thanks to more effective drugs and screening tools and regular mass screening. However, this potentially jeopardizes HAT control activities, especially community engagement. Methods: We used an ecological model framework to understand how various factors shape communities’ knowledge, perceptions, and behavior in this low endemicity context. Community members, frontline health providers, and policymakers were consulted using an ethnographic approach. Results: Communities in endemic areas are knowledgeable about causes, symptoms, and treatment of HAT, but this was more limited among young people. Few are aware of new HAT treatment or screening techniques. Participation in mass screening has declined due to many factors including fear and a lack of urgency, given the low numbers of cases. Delays in seeking medical care are due to confusion of HAT symptoms with those of other diseases and belief that HAT is caused by witchcraft. Conclusions: Community members see their role more in terms of vector control than participation in screening, referral, or accepting treatment. We propose recommendations for achieving sustainable community engagement, including development of an information and communication strategy and empowerment of communities to take greater ownership of HAT control activities.
Clinical research on neglected tropical diseases is a challenge in low-resource countries, and the contribution of clinical and operational research to health system strengthening is poorly documented. Developing new, simple, safe, and effective treatments may improve the effectiveness of health systems, and conducting research directly in health structures may have an additional impact. This study describes the process of conducting clinical trials in the Democratic Republic of Congo (DRC) in compliance with international standards, and the role of the trials in strengthening health system functions, including governance, human resources, health information, provision of care, and the equipping of health services with the necessary supplies and infrastructure. We conclude that conducting clinical trials in endemic areas has not only reinforced and supported the aim of conducting high-level clinical research in endemic countries, but has also brought lasting benefits to researchers, staff, and hospitals, as well as to broader health systems, which have positive knock-on effect on patients outside of the clinical trials and their communities. Sustainability, however, remains a challenge in an underfunded health system, especially with respect to specialized equipment. Clinical research in most of sub-Saharan Africa is highly dependent on international input and external technical support; there are areas of weaknesses in trial design and documentation, as well as in data management and analysis. Financing remains a critical issue, as African investigators have difficulties in directly accessing sources of international research funding.
Background: The World Health Organization aims for the elimination of Human African Trypanosomiasis (HAT) as a public health problem by 2020 and for full elimination (absence of new cases) by 2030. One of strategies to achieve this is the active follow-up of all HAT serological suspects found during passive screening who have never been re-tested for parasitology. This is important because these cases can maintain HAT transmission and may be responsible for reemergence of the disease. Methods: In order to improve case finding at low cost in the targeted population, a general recall was transmitted to aparasitemic serological suspects about the availability of confirmation services at the general referral hospital. Transport was facilitated for re-testing. The initial examinations were carried out in Health Centers from Bagata Health Zone (HZ) in the Democratic Republic of the Congo between January 2017 and April 2019. This strategy of using a HZ team has not been previously documented. Results: From a total sample of 74 serological suspects listed by the health centers, 36 cases were re-examined at the general reference hospital; 19% (7/36) self-presented and 81% (29/36) were actively followed up by HZ personnel. Of those re-examined at the general reference hospital, 39% (14/36) resulted in a parasitologically confirmed case. Of the 14 people diagnosed with HAT, 14% (2/14) self-presented and the remaining 86% (12/14) were diagnosed in suspects who were actively followed up. This new strategy of facilitating transport from the villages added value by contributing to the detection of 12 HAT cases, compared to the passive approach, waiting for self-reference, which resulted in the detection of 2 new HAT cases. The cost per detected patient was 70 USD from the group of 7 suspects who self-presented for testing at the hospital and 346 USD per detected case for the group of 29 patients who were actively followed up by health zone staff. Conclusion: Targeted active follow-up of aparasitemic serological suspects by HZ teams is a cost-effective and promising approach to identifying additional cases of HAT in areas of very low prevalence, which would contribute to the HAT elimination goal set by the World Health Organization.
Background T.b. gambiense human African trypanosomiasis (g-HAT) is a neglected tropical disease targeted by the World Health Organization (WHO) for elimination by 2030. The first all-oral treatment for g-HAT, fexinidazole (developed by DNDi), received a marketing authorization in DRC in December 2018 and was included as first-line treatment in the new WHO-HAT treatment guidelines and added to the 2019 WHO-Essential Medicines Lists. DNDi collaborated with WHO to support five HAT-endemic countries through EDCTP2. Methods The project focused on healthcare capacity-strengthening and coordination support for the appropriate use of fexinidazole, and fexinidazole surveillance and national pharmacovigilance systems support, including for the timely and efficient reporting of adverse reactions through the HAT Platform as a communication mechanism, trainings, and reinforced pharmacovigilance channels. Regarding fexinidazole surveillance, selected health facilities’ health workers were trained on WHO-HAT treatment guidelines and safety notification, including choice of internationally compatible software with Vigibase repository. Support to national pharmacovigilance systems was provided to five target countries (DRC, Guinea, Angola, CAR, and South Sudan) through baseline assessments, set-up, and training of five national and six regional pharmacovigilance units in the DRC coordinated with the DRC national PV team. Results During the last two years of the project, 630 healthcare workers from 243 facilities were trained on the new WHO-HAT treatment guidelines, including fexinidazole, in the five target countries. 556 HAT patients were treated with fexinidazole, and notifications of adverse events were sent to WHO and national pharmacovigilance systems. In addition, the five national pharmacovigilance systems were equipped and trained. Conclusion This project enabled the reinforcement of five countries’ national pharmacovigilance systems and development of collaborative networking to extend safety surveillance to all drugs. Healthcare workers in all five countries were trained in the use of fexinidazole, and HAT patients are now being effectively diagnosed and treated.